Research recommendation(s) from an individual piece of guidance
|Guidance||Type 2 diabetes in adults: management|
|Date issued||December 2015|
Research recommendations coming out of this guidance
The effects of stopping and/or switching drug treatments to control blood glucose levels:- In adults with type 2 diabetes, what are the effects of stopping and/or switching drug treatments to control blood glucose levels, and what criteria should inform the decision?
Non-metformin-based drug treatment combinations to control blood glucose levels:-
In adults with type 2 diabetes, what treatment combinations (for example, glucagon-like peptide-1 [GLP-1] mimetics and insulin combination therapy with meglitinides) are most effective when initial drug treatment with non-metformin monotherapy fails to adequately control blood glucose levels?
Drug treatment (third intensification) for when blood glucose levels are inadequately controlled by 3 oral antidiabetic drugs and/or insulin combinations:- When third intensification of treatment is indicated, which blood glucose lowering therapies should be used to control blood glucose levels?
Long-term outcomes associated with blood glucose lowering agents:- In adults with type 2 diabetes, what are the long-term effects of blood glucose lowering therapies such as dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium–glucose cotransporter-2 (SGLT-2) inhibitors and meglitinides?
Self-monitoring of blood glucose levels:- What is the optimal frequency for self-monitoring of blood glucose in adults with type 2 diabetes?